Researcher Profile

Researcher Profile

Rebecca Phaeton, MD

Rebecca Phaeton, MD

Assistant Professor, Department of Obstetrics and Gynecology
Assistant Professor, Department of Microbiology and Immunology
Scientific Program:Experimental Therapeutics
Disease Teams:
Gynecological Cancer

Research Interests

  • Neoplasms
  • Uterine Cervical Neoplasms
  • Oncogene Proteins
  • Therapeutics
  • Radioimmunotherapy
  • Antibodies
  • Ovarian Neoplasms
  • Growth
  • Monoclonal Antibodies
  • Rhenium
  • Human papillomavirus 16
  • Incidence

Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Recent Publications


Jiang, Z, Albanese, J, Kesterson, J, Warrick, J, Karabakhtsian, R, Dadachova, E & Phaeton, R 2019, 'Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer', Translational Oncology, vol. 12, no. 10, pp. 1289-1295.


Worley, BL, Kim, YS, Mardini, J, Zaman, R, Leon, KE, Vallur, PG, Nduwumwami, A, Warrick, J, Timmins, PF, Kesterson, J, Phaeton, R, Lee, NY, Walter, V, Endres, L, Mythreye, K, Aird, K & Hempel, N 2018, 'GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment', Redox Biology.






Phaeton, R, Gutierrez, J, Jiang, Z, Karabakhtsian, RG, Albanese, J, Sunkara, J, Fisher, DR, Goldberg, GL & Dadachova, E 2015, 'Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer', Immunotherapy, vol. 7, no. 6, pp. 631-640.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)